Immunotherapy for Cat Allergy: Every Option, Ranked by Evidence

Yes, allergy shots (SCIT) can reduce cat allergy symptoms meaningfully, but the evidence is classified as moderate rather than strong because the supporting studies have been relatively small. The key finding from Varney et al. (Clin Exp Allergy 1997) and Ewbank et al. (JACI 2003) is that only the 15 mcg Fel d 1 maintenance dose produces consistent results — lower doses are largely ineffective. Patients on correctly dosed cat SCIT experience approximately 60-72% symptom reduction during controlled cat exposure. EAACI guidelines give cat immunotherapy a conditional recommendation. Real-world effectiveness also depends on completing at least 3 years of treatment, as with all immunotherapy. It is important that a board-certified allergist confirms Fel d 1 sensitization through skin or blood testing before beginning.

No FDA-approved sublingual immunotherapy tablet exists for cat allergy as of 2025, which is a significant treatment gap compared to grass pollen (three FDA-approved tablets) or dust mite (one FDA-approved tablet). Patients and clinicians rely on off-label sublingual drops compounded from cat allergen extract, which lack the standardized phase-3 trial evidence base that the approved tablets possess. Small studies suggest off-label cat SLIT drops may provide modest symptom relief, but a board-certified allergist should guide the decision between SCIT (better evidence) and off-label SLIT drops (more convenient). Investigational approaches including recombinant Fel d 1 hypoallergenic vaccines are in early-phase trials but not commercially available.

Cat-SPIRE was a synthetic peptide immunotherapy developed by Circassia designed to desensitize cat-allergic patients using short Fel d 1 peptide fragments rather than whole allergen extract. In 2016, the phase III trial (n=1,245) failed its primary endpoint: both active-dose regimens (4-dose and 8-dose) produced symptom reductions during cat-room challenge that were statistically indistinguishable from placebo. Investigators attributed the failure to an unexpectedly large placebo response in the trial, rather than a lack of biological activity. Immunologic markers did change in the active arm. Circassia subsequently abandoned allergy peptide development. The failure was a significant setback for the field but did not undermine the evidence for conventional cat SCIT, which uses a different mechanism and established allergen extract rather than synthetic peptides.

The dose-response relationship for cat SCIT is unusually steep and well-documented. Ewbank et al. (JACI 2003) conducted a randomized dose-finding trial comparing 15 mcg, 3.0 mcg, and 0.6 mcg Fel d 1 maintenance doses. Only the 15 mcg dose produced consistent immunologic and clinical responses. Patients at 3.0 mcg showed partial response, and 0.6 mcg was equivalent to placebo for both symptom scores and immunologic markers. This matters practically because under-dosing — which can happen if allergen extract potency is not carefully calibrated — results in little to no clinical benefit despite months of injections. Standardized cat extracts in the US are calibrated by Fel d 1 content per FDA Allergenic Products requirements, but a board-certified allergist should verify that your specific treatment vials are targeting the therapeutic dose range.

Most patients receiving cat SCIT notice some reduction in symptoms within the first 3-6 months of treatment, which typically corresponds to the buildup phase reaching or approaching the maintenance dose. Meaningful clinical benefit — the 60-72% symptom reduction observed in controlled trials — is generally seen after sustained maintenance dosing, which begins after the 3-6 month buildup phase. Full disease modification, meaning long-lasting relief that persists even after stopping treatment, requires at least 3 years of immunotherapy per EAACI guidelines and the AAAAI/ACAAI Joint Task Force Practice Parameter. Stopping after 1-2 years is unlikely to produce durable post-treatment benefit. Patients should discuss realistic expectation timelines with their allergist before beginning.

Cat allergy immunotherapy can be pursued by patients who own cats, but the evidence for benefit in high-continuous-exposure settings is mostly extrapolated from controlled cat-room challenge studies rather than real-world cat-ownership trials. Wood et al. (JACI 1998) documented that even HEPA filtration and regular washing reduce but do not eliminate Fel d 1 levels in cat-owning households, so ongoing allergen exposure continues during treatment. This is generally not considered a contraindication to SCIT — in fact, some allergists argue that ongoing low-level exposure may enhance the desensitization process — but expectations should be calibrated: immunotherapy is not a substitute for environmental controls. A board-certified allergist can help determine whether the expected benefit outweighs the risk in your specific situation.

Cat allergy shots carry the same spectrum of side effects as allergy shots for any allergen. Local injection-site reactions — redness, swelling, itching at the shot location — occur in 30-80% of patients and are considered a normal part of treatment; applying ice and taking an over-the-counter antihistamine typically manages these effectively. Systemic reactions affecting the whole body occur in roughly 0.1% of injection visits. Anaphylaxis, the most serious reaction, is rare but is why a short post-injection observation period and a confirmed epinephrine auto-injector matter after every dose. Patients with poorly controlled asthma are at higher risk for severe reactions and should ensure their asthma is well managed before beginning SCIT. With at-home SCIT through Curex, eligible patients self-inject at home after a prescribed epinephrine auto-injector is confirmed on hand, and the first dose and every dose change are supervised live over Zoom by the prescribing allergist.